Trial Outcomes & Findings for Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant (NCT NCT05959447)

Results Overview

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

45 participants

Primary outcome timeframe

Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

Results posted on

2025-03-26

Participant Flow

A total of 45 participants were enrolled in the study (25 participants in Part 1 and 20 participants in Part 2). Only 32 participants (13 participants were never dosed) were dosed into the study to receive either camlipixant + gemfibrozil or dabigatran etexilate+ camlipixant creating the Safety Population. (The safety population included all participants who received at least one dose of any study drug).

Participant milestones

Participant milestones
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg Participants received single oral dose of dabigatran etexilate 150 mg capsule on Day 1, followed by repeated oral doses of camlipixant 50 mg tablet twice daily (BID) (total daily dose of 100 mg) from Days 5 to 9, with co-administration of a single oral dose of dabigatran etexilate 150 mg capsule with the morning dose of camlipixant on Day 10. There was a washout of at least 4 days between the dose of dabigatran etexilate on Day 1 and the dose of camlipixant on Day 5.
Part 1 (Up to Day 21) STARTED	25	0
Part 1 (Up to Day 21) Safety Population	16	0
Part 1 (Up to Day 21) COMPLETED	15	0
Part 1 (Up to Day 21) NOT COMPLETED	10	0
Part 2 (Up to Day 22) STARTED	0	20
Part 2 (Up to Day 22) Safety Population	0	16
Part 2 (Up to Day 22) COMPLETED	0	14
Part 2 (Up to Day 22) NOT COMPLETED	0	6

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg Participants received single oral dose of dabigatran etexilate 150 mg capsule on Day 1, followed by repeated oral doses of camlipixant 50 mg tablet twice daily (BID) (total daily dose of 100 mg) from Days 5 to 9, with co-administration of a single oral dose of dabigatran etexilate 150 mg capsule with the morning dose of camlipixant on Day 10. There was a washout of at least 4 days between the dose of dabigatran etexilate on Day 1 and the dose of camlipixant on Day 5.
Part 1 (Up to Day 21) Adverse Event	1	0
Part 1 (Up to Day 21) Enrolled but did not receive study treatment	9	0
Part 2 (Up to Day 22) Adverse Event	0	2
Part 2 (Up to Day 22) Enrolled but did not receive study treatment	0	4

Baseline Characteristics

Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg n=16 Participants Participants received single oral dose of dabigatran etexilate 150 mg capsule on Day 1, followed by repeated oral doses of camlipixant 50 mg tablet twice daily (BID) (total daily dose of 100 mg) from Days 5 to 9, with co-administration of a single oral dose of dabigatran etexilate 150 mg capsule with the morning dose of camlipixant on Day 10. There was a washout of at least 4 days between the dose of dabigatran etexilate on Day 1 and the dose of camlipixant on Day 5.	Total n=32 Participants Total of all reporting groups
Age, Customized 23 to 54 years	16 Participants n=5 Participants	16 Participants n=7 Participants	32 Participants n=5 Participants
Sex: Female, Male Female	7 Participants n=5 Participants	7 Participants n=7 Participants	14 Participants n=5 Participants
Sex: Female, Male Male	9 Participants n=5 Participants	9 Participants n=7 Participants	18 Participants n=5 Participants
Race/Ethnicity, Customized All Other Races	2 Participants n=5 Participants	2 Participants n=7 Participants	4 Participants n=5 Participants
Race/Ethnicity, Customized White	14 Participants n=5 Participants	14 Participants n=7 Participants	28 Participants n=5 Participants

PRIMARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

Population: The PK parameter Population included all participants for whom the Day 1 and Day 9 PK profiles of the camlipixant could be adequately characterized, specifically, when administered alone and in combination with gemfibrozil (Part 1)

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC-inf) of Camlipixant Day 1	4886.66 Hours*nanograms per milliliter Geometric Coefficient of Variation 28.69	—	—
Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC-inf) of Camlipixant Day 9	10642.07 Hours*nanograms per milliliter Geometric Coefficient of Variation 24.17	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

Population: The PK parameter Population included all participants for whom the Day 1 and Day 9 PK profiles of the camlipixant could be adequately characterized, specifically, when administered alone and in combination with gemfibrozil (Part 1)

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t]) of Camlipixant Day 1	4846.83 Hours*nanograms per milliliter Geometric Coefficient of Variation 28.84	—	—
Part 1: Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t]) of Camlipixant Day 9	10541.57 Hours*nanograms per milliliter Geometric Coefficient of Variation 24.44	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

Population: The PK parameter Population included all participants for whom the Day 1 and Day 9 PK profiles of the camlipixant could be adequately characterized, specifically, when administered alone and in combination with gemfibrozil (Part 1)

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Maximal Observed Concentration (Cmax) of Camlipixant Day 1	1078 Nanograms per milliliter Geometric Coefficient of Variation 25.02	—	—
Part 1: Maximal Observed Concentration (Cmax) of Camlipixant Day 9	1303 Nanograms per milliliter Geometric Coefficient of Variation 25.65	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: AUC(0-Infinity) of Free Dabigatran Day 1	943.49 Hours*nanograms per milliliter Geometric Coefficient of Variation 52.12	—	—
Part 2: AUC(0-Infinity) of Free Dabigatran Day 10	1055.20 Hours*nanograms per milliliter Geometric Coefficient of Variation 43.81	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: AUC(0-t) of Free Dabigatran Day 1	920.18 Hours*nanograms per milliliter Geometric Coefficient of Variation 53.11	—	—
Part 2: AUC(0-t) of Free Dabigatran Day 10	1031.89 Hours*nanograms per milliliter Geometric Coefficient of Variation 45.03	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Cmax of Free Dabigatran Day 1	110 Nanograms per milliliter Geometric Coefficient of Variation 53.53	—	—
Part 2: Cmax of Free Dabigatran Day 10	125 Nanograms per milliliter Geometric Coefficient of Variation 47.75	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: AUC(0-Infinity) of Total Dabigatran Day 1	1165.82 Hours*nanograms per milliliter Geometric Coefficient of Variation 52.34	—	—
Part 2: AUC(0-Infinity) of Total Dabigatran Day 10	1339.35 Hours*nanograms per milliliter Geometric Coefficient of Variation 41.21	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: AUC(0-t) of Total Dabigatran Day 1	1139.80 Hours*nanograms per milliliter Geometric Coefficient of Variation 53.51	—	—
Part 2: AUC(0-t) of Total Dabigatran Day 10	1316.80 Hours*nanograms per milliliter Geometric Coefficient of Variation 41.83	—	—

PRIMARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Cmax of Total Dabigatran Day 1	135 Nanograms per milliliter Geometric Coefficient of Variation 54.20	—	—
Part 2: Cmax of Total Dabigatran Day 10	160 Nanograms per milliliter Geometric Coefficient of Variation 42.42	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

Population: The PK parameter Population included all participants for whom the Day 1 and Day 9 PK profiles of the camlipixant could be adequately characterized, specifically, when administered alone and in combination with gemfibrozil (Part 1)

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Time to Reach Maximum Observed Concentration (Tmax) of Camlipixant Day 1	0.750 Hours Interval 0.5 to 2.0	—	—
Part 1: Time to Reach Maximum Observed Concentration (Tmax) of Camlipixant Day 9	0.750 Hours Interval 0.5 to 2.5	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

Population: The PK parameter Population included all participants for whom the Day 1 and Day 9 PK profiles of the camlipixant could be adequately characterized, specifically, when administered alone and in combination with gemfibrozil (Part 1)

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Terminal Elimination Half-Life (T1/2) Following Administration of Camlipixant Day 1	5.56 Hours Geometric Coefficient of Variation 31.80	—	—
Part 1: Terminal Elimination Half-Life (T1/2) Following Administration of Camlipixant Day 9	9.56 Hours Geometric Coefficient of Variation 18.60	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

Population: The PK parameter Population included all participants for whom the Day 1 and Day 9 PK profiles of the camlipixant could be adequately characterized, specifically, when administered alone and in combination with gemfibrozil (Part 1)

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Camlipixant Day 1	0.58 Percentage of AUC extrapolation Geometric Coefficient of Variation 104.04	—	—
Part 1: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Camlipixant Day 9	0.59 Percentage of AUC extrapolation Geometric Coefficient of Variation 109.24	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

Population: The PK parameter Population included all participants for whom the Day 1 and Day 9 PK profiles of the camlipixant could be adequately characterized, specifically, when administered alone and in combination with gemfibrozil (Part 1)

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Terminal Elimination Rate Constant of Camlipixant (Kel) Day 1	0.1247 h^-1 Geometric Coefficient of Variation 31.80	—	—
Part 1: Terminal Elimination Rate Constant of Camlipixant (Kel) Day 9	0.0725 h^-1 Geometric Coefficient of Variation 18.60	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

Population: The PK parameter Population included all participants for whom the Day 1 and Day 9 PK profiles of the camlipixant could be adequately characterized, specifically, when administered alone and in combination with gemfibrozil (Part 1)

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Apparent Clearance (CL/F) of Camlipixant Day 1	10.23 Liters per hour Geometric Coefficient of Variation 28.69	—	—
Part 1: Apparent Clearance (CL/F) of Camlipixant Day 9	4.70 Liters per hour Geometric Coefficient of Variation 24.17	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 48, 72 hours post-dose on Day 1 and Day 9

Population: The PK parameter Population included all participants for whom the Day 1 and Day 9 PK profiles of the camlipixant could be adequately characterized, specifically, when administered alone and in combination with gemfibrozil (Part 1)

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Apparent Volume of Distribution (Vz/F) of Camlipixant Day 1	82.06 Liters Geometric Coefficient of Variation 22.57	—	—
Part 1: Apparent Volume of Distribution (Vz/F) of Camlipixant Day 9	64.80 Liters Geometric Coefficient of Variation 23.69	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Tmax of Free Dabigatran Day 1	2.000 Hours Interval 1.5 to 3.5	—	—
Part 2: Tmax of Free Dabigatran Day 10	2.000 Hours Interval 1.5 to 3.0	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: T1/2 Following Administration Free Dabigatran Day 1	10.49 Hours Geometric Coefficient of Variation 18.23	—	—
Part 2: T1/2 Following Administration Free Dabigatran Day 10	9.18 Hours Geometric Coefficient of Variation 9.16	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Free Dabigatran Day 1	2.22 Percentage of AUC extrapolation Geometric Coefficient of Variation 49.87	—	—
Part 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Free Dabigatran Day 10	1.95 Percentage of AUC extrapolation Geometric Coefficient of Variation 52.63	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Kel Free Dabigatran Day 1	0.0660 h^-1 Geometric Coefficient of Variation 18.23	—	—
Part 2: Kel Free Dabigatran Day 10	0.0755 h^-1 Geometric Coefficient of Variation 9.16	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: CL/F Free Dabigatran Day 1	158.98 Liters per hour Geometric Coefficient of Variation 52.12	—	—
Part 2: CL/F Free Dabigatran Day 10	142.15 Liters per hour Geometric Coefficient of Variation 43.81	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Vz/F Free Dabigatran Day 1	2407.03 Liters Geometric Coefficient of Variation 54.73	—	—
Part 2: Vz/F Free Dabigatran Day 10	1883.56 Liters Geometric Coefficient of Variation 43.72	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Tmax of Total Dabigatran Day 1	2.000 Hours Interval 1.0 to 3.5	—	—
Part 2: Tmax of Total Dabigatran Day 10	2.000 Hours Interval 1.0 to 3.0	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: T1/2 Following Administration of Total Dabigatran Day 1	11.04 Hours Geometric Coefficient of Variation 30.01	—	—
Part 2: T1/2 Following Administration of Total Dabigatran Day 10	10.21 Hours Geometric Coefficient of Variation 16.90	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Total Dabigatran Day 1	1.93 Percentage of AUC extrapolation Geometric Coefficient of Variation 59.97	—	—
Part 2: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (%AUC Extrapolation) of Total Dabigatran Day 10	1.58 Percentage of AUC extrapolation Geometric Coefficient of Variation 37.14	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Kel of Total Dabigatran Day 1	0.0628 h^-1 Geometric Coefficient of Variation 30.01	—	—
Part 2: Kel of Total Dabigatran Day 10	0.0679 h^-1 Geometric Coefficient of Variation 16.90	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: CL/F of Total Dabigatran Day 1	128.66 Liters per hour Geometric Coefficient of Variation 52.34	—	—
Part 2: CL/F of Total Dabigatran Day 10	111.99 Liters per hour Geometric Coefficient of Variation 41.21	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25 , 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60, 72 hours post-dose on Day 1 and Day 10

Population: The PK parameter Population included all participants for whom the Day 1 and Day 10 PK profiles of the dabigatran could be adequately characterized, specifically, when administered alone and in combination with camlipixant (Part 2). Only those participants who were measured and analyzed (i.e., contributed data reported in table) were included in 'Overall Number of Participants Analyzed' field.

Blood samples were collected at indicated time points for PK analysis of Dabigatran. PK analysis was conducted using standard non-compartmental methods.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=14 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Vz/F of Total Dabigatran Day 1	2048.49 Liters Geometric Coefficient of Variation 61.16	—	—
Part 2: Vz/F of Total Dabigatran Day 10	1649.21 Liters Geometric Coefficient of Variation 37.35	—	—

SECONDARY outcome

Timeframe: Day 1 post-dose until Day 5 pre-dose of gemfibrozil [camlipixant 50mg]; from Day 5 dosing until Day 9 pre-dose of camlipixant [gemfibrozil 600mg]; from camlipixant dosing on Day 9 until end of study [Day 21] [camlipixant 50mg+gemfibrozil 600mg]

Population: Safety Population consisted of all participants who received at least one dose of any study drug.

An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per medical and scientific judgement. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. AEMIs for this study includes the following, but not limited to taste disturbances (dysgeusia, hypogeusia, ageusia), oral paresthesia and oral hypoesthesia Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg n=16 Participants Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg n=16 Participants Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs) TEAEs	1 Participants	6 Participants	5 Participants
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs) TESAEs	0 Participants	0 Participants	1 Participants
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs) TEAEMIs	0 Participants	0 Participants	1 Participants

SECONDARY outcome

Timeframe: Day1 postdose until Day5 predose of camlipixant [dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran [camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day 22][dabigatran etexilate 150mg+camlipixant 50mg]

Population: Safety population consisted of all participants who received at least one dose of any study drug.

An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per medical and scientific judgement. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. AEMIs for this study includes the following, but not limited to: taste disturbances (dysgeusia, hypogeusia, ageusia), oral paresthesia and oral hypoesthesia Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg n=15 Participants Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg n=14 Participants Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Number of Participants With TEAEs, TESAEs and TEAEMIs TEAEs	4 Participants	6 Participants	0 Participants
Part 2: Number of Participants With TEAEs, TESAEs and TEAEMIs TESAEs	0 Participants	0 Participants	0 Participants
Part 2: Number of Participants With TEAEs, TESAEs and TEAEMIs TEAEMIs	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Day 5, Day 9 pre-dose and 1 hour post-dose, Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings Day 5	0 Participants	—	—
Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings Day 9,1-Hour Post-dose	0 Participants	—	—
Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings Day 9, Pre-dose	0 Participants	—	—
Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings Day 12	0 Participants	—	—

SECONDARY outcome

Timeframe: Day 5, Day 10 and Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings Day 13	0 Participants	—	—
Part 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings Day 5	0 Participants	—	—
Part 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings Day 10	0 Participants	—	—

SECONDARY outcome

Timeframe: Day 9 and Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), and Heart Rate Day 9	0 Participants	—	—
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), and Heart Rate Day 12	0 Participants	—	—

SECONDARY outcome

Timeframe: Day 10 and Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: DBP, SBP, and Heart Rate Day 13	0 Participants	—	—
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: DBP, SBP, and Heart Rate Day 10	0 Participants	—	—

SECONDARY outcome

Timeframe: Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature	0 Participants	—	—

SECONDARY outcome

Timeframe: Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination	1 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Number of Participants With Abnormal Clinically Significant Changes During Physical Examination	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters	3 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters	1 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international normalized ratio (INR), and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international normalized ratio (INR), and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 12

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis	0 Participants	—	—

SECONDARY outcome

Timeframe: Up to Day 13

Population: Safety population consisted of all participants who received at least one dose of any study drug.

Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

Outcome measures

Outcome measures
Measure	Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg n=16 Participants Participants received a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. There was a washout of at least 4 days between the dose of camlipixant on Day 1 and the dose of gemfibrozil on Day 5.	Part 1: Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis	0 Participants	—	—

Adverse Events

Part 1: Camlipixant 50 mg

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Part 1: Gemfibrozil 600 mg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg

Serious events: 1 serious events

Other events: 5 other events

Deaths: 0 deaths

Part 2: Dabigatran Etexilate 150 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Part 2: Camlipixant 50 mg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

Part 2: Dabigatran Etexilate 150 mg+ Camlipixant 50 mg

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Part 1: Camlipixant 50 mg n=16 participants at risk Participants received a single oral dose of 50 mg camlipixant tablet on Day 1.	Part 1: Gemfibrozil 600 mg n=16 participants at risk Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11.	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg n=16 participants at risk Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)	Part 2: Dabigatran Etexilate 150 mg n=16 participants at risk Participants received single oral dose of dabigatran etexilate 150 mg capsule on Day 1	Part 2: Camlipixant 50 mg n=15 participants at risk Participants received repeated oral doses of camlipixant 50 mg tablet twice daily (BID) (total daily dose of 100 mg) from Days 5 to 10.	Part 2: Dabigatran Etexilate 150 mg+ Camlipixant 50 mg n=14 participants at risk Participants received repeated oral doses of camlipixant 50 mg tablet twice daily (BID) (total daily dose of 100 mg) from Days 5 to 9, with co-administration of a single oral dose of dabigatran etexilate 150 mg capsule with the morning dose of camlipixant on Day 10. Participants were followed up for adverse events until end of study (up to Day 22).
Investigations Hepatic enzyme increased	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.

Other adverse events

Other adverse events
Measure	Part 1: Camlipixant 50 mg n=16 participants at risk Participants received a single oral dose of 50 mg camlipixant tablet on Day 1.	Part 1: Gemfibrozil 600 mg n=16 participants at risk Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11.	Part 1: Camlipixant 50 mg+ Gemfibrozil 600 mg n=16 participants at risk Participants received repeated oral doses of gemfibrozil 600 mg tablet twice daily (BID), every 12 hours, (total daily dose of 1200 mg) on Days 5 to 11, with co-administration of a single oral dose of camlipixant 50 mg tablet with the gemfibrozil on Day 9. Participants were followed up for adverse events until end of study (up to Day 21)	Part 2: Dabigatran Etexilate 150 mg n=16 participants at risk Participants received single oral dose of dabigatran etexilate 150 mg capsule on Day 1	Part 2: Camlipixant 50 mg n=15 participants at risk Participants received repeated oral doses of camlipixant 50 mg tablet twice daily (BID) (total daily dose of 100 mg) from Days 5 to 10.	Part 2: Dabigatran Etexilate 150 mg+ Camlipixant 50 mg n=14 participants at risk Participants received repeated oral doses of camlipixant 50 mg tablet twice daily (BID) (total daily dose of 100 mg) from Days 5 to 9, with co-administration of a single oral dose of dabigatran etexilate 150 mg capsule with the morning dose of camlipixant on Day 10. Participants were followed up for adverse events until end of study (up to Day 22).
Cardiac disorders Palpitations	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Investigations Thyroxine free decreased	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Nervous system disorders Dysgeusia	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Nervous system disorders Headache	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.7% 1/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Psychiatric disorders Affect lability	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Gastrointestinal disorders Constipation	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.7% 1/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Gastrointestinal disorders Abdominal pain	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	13.3% 2/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Gastrointestinal disorders Aphthous ulcer	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Gastrointestinal disorders Faeces soft	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.7% 1/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Gastrointestinal disorders Flatulence	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Gastrointestinal disorders Gastrointestinal sounds abnormal	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
General disorders Feeling hot	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
General disorders Chest discomfort	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
General disorders Feeling abnormal	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Investigations Alanine aminotransferase increased	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.7% 1/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Investigations Aspartate aminotransferase increased	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.7% 1/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Investigations Blood pressure increased	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Investigations Heart rate increased	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Gastrointestinal disorders Diarrhoea	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.7% 1/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Gastrointestinal disorders Nausea	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Investigations Gamma-glutamyltransferase increased	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.7% 1/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Investigations SARS-CoV-2 test positive	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Nervous system disorders Somnolence	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Eye disorders Dry eye	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.7% 1/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Eye disorders Photophobia	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.2% 1/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Injury, poisoning and procedural complications Procedural dizziness	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.7% 1/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Renal and urinary disorders Pollakiuria	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.7% 1/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.
Skin and subcutaneous tissue disorders Hand dermatitis	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/16 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	6.7% 1/15 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.	0.00% 0/14 • Part1(Day1 postdose until Day5 predose of gemfibrozil [Camlipixant 50mg];from Day5 dosing until Day9 predose of camlipixant[Gemfibrozil 600mg];from camlipixant dosing on Day9 until end of study[Day21] [Camlipixant 50mg+Gemfibrozil 600mg]) and Part2(Day1 postdose until Day5 predose of camlipixant[Dabigatran etexilate 150mg];from Day5 dosing until Day10 predose of dabigatran[Camlipixant 50mg];from dabigatran dosing on Day10 until end of study [Day22] [Dabigatran etexilate 150mg+camlipixant 50mg]) Safety Population comprised of all participants who received at least one dose of any study drug. AEs were reported treatment-wise.

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER